Inhibitory peptides of viral infection
Disclosed are methods of treating and/or inhibiting a viral infection in a subject. The methods include administering a therapeutically effective amount of heparin-binding peptide. Also disclosed herein are methods for blocking viral binding to a cell. Further disclosed are anti-viral compositions for administration to a subject infected with a virus. Administration of the anti-viral composition inhibits viral infection of the subject.
1. A heparin binding peptide consisting of an amino acid sequence at least 95% identical to the amino acid sequence set forth as any one of SEQ ID NOs: 3-10.
2. The heparin binding peptide of claim 1 , wherein administration of the heparin binding peptide to a subject infected with a virus reduces viral infection in the subject.
3. The heparin binding peptide of claim 2 , wherein administration of the heparin binding peptide to the subject infected with the virus reduces viral infection in the subject by at least 60%.
4. The heparin binding peptide of claim 2 , wherein the virus is an enveloped DNA virus or enveloped RNA virus.
5. The heparin binding peptide of claim 1 , wherein administration of the heparin binding peptide to a subject infected with herpesvirus reduces herpesvirus infection in the subject.
6. The heparin binding peptide of claim 1 , wherein administration of the heparin binding peptide to a subject infected with cytomegalovirus reduces cytomegalovirus infection in the subject.
7. The heparin binding peptide of claim 1 , wherein administration of the heparin binding peptide to a subject infected human immunodeficiency virus (HIV) infection reduces HIVs infection in the subject.
8. The heparin binding peptide of claim 1 , wherein the heparin-binding peptide is a D-form peptide.
9. A heparin binding peptide comprising an amino acid sequence at least 95% identical to the amino acid sequence set forth as any one of SEQ ID NO: 7, SEQ ID NO: 9, and SEQ ID NO: 10.
10. The heparin binding peptide of claim 9 , wherein administration of the heparin binding peptide to a subject infected with a virus reduces viral infection in the subject.
11. The heparin binding peptide of claim 10 , wherein administration of the heparin binding peptide to the subject infected with the virus reduces viral infection in the subject by at least 60%.
12. The heparin binding peptide of claim 10 , wherein the virus is an enveloped DNA virus or enveloped RNA virus.
13. The heparin binding peptide of claim 9 , wherein administration of the heparin binding peptide to a subject infected with herpesvirus reduces herpesvirus infection in the subject.
14. The heparin binding peptide of claim 9 , wherein administration of the heparin binding peptide to a subject infected with cytomegalovirus reduces cytomegalovirus infection in the subject.
15. The heparin binding peptide of claim 9 , wherein administration of the heparin binding peptide to a subject infected human immunodeficiency virus (HIV) infection reduces HIVs infection in the subject.
16. The heparin binding peptide of claim 9 , wherein the heparin-binding peptide is a D-form peptide.